Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-02-07
2006-02-07
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S042000, C514S045000, C514S046000, C514S047000, C514S048000, C514S049000, C514S050000, C514S051000, C514S052000
Reexamination Certificate
active
06995145
ABSTRACT:
The invention provides methods and compositions for modulating the activity of therapeutic agents for the treatment of a cancer by administering one or more agents that (either alone or in combination) induces telomere damage and inhibits telomerase activity in the cancer cell. The method initially uses, e.g., a telomere damage-inducing agent such as paclitaxel, and a telomerase inhibitory agent such as AZT. The invention also provides methods for identifying other agents with telomere damage-inducing activity and/or telomerase inhibitory activity (as well as and compositions having such activity), for use in the treatment of cancer.
REFERENCES:
patent: 5645986 (1997-07-01), West et al.
patent: 5756537 (1998-05-01), Gill
patent: 5869461 (1999-02-01), Cheng et al.
patent: 5972605 (1999-10-01), Villeponteau
patent: 6007989 (1999-12-01), West et al.
patent: 6022709 (2000-02-01), de Lange et al.
patent: 6046307 (2000-04-01), Shay et al.
patent: 6150398 (2000-11-01), Vande Woude et al.
patent: 6749868 (2004-06-01), Desai et al.
patent: WO 96/01835 (1996-01-01), None
patent: WO 96/19580 (1996-06-01), None
patent: WO 96/41016 (1996-12-01), None
patent: WO 97/38013 (1997-10-01), None
patent: WO 98/14593 (1998-04-01), None
patent: WO 98/21343 (1998-05-01), None
patent: WO 99/09212 (1999-02-01), None
Gomez, Daniel E. et al., “Irreversible Telomere Shortening by 3′-Azido-2′,3′-Dideoxythymidine (AZT) Treatment” Biochemical and Biophysical Research Communications, May 1998, 246, 107-110.
Melana, Stella M. et al., “Inhibition of Cell Growth and Telomerase Activity of Breast Cancer Cells in Vitro by 3′-Azido-3′-deoxythymidine” Clinical Cancer Research, Mar. 1998, 4, 693-696.
The Merck Index, 1996, entry Nos. 7117, 8958 and 10252.
Pai, Rekha B. et al., “Telomerase from Human Leukemia Cells: Properties and Its Interactions with Deoxynucleoside Analogues” Cancer Research, May 1998, 58, 1909-1913.
Strahl, Catherine et al, “Effects of Reverse Transcriptase Inhibitors on Telomere Length and Telomerase Activity in Two Immortalized Human Cell Lines” Molecular and Cellular Biology, Jan. 1996, 16 (1), 53-65.
Gschwentner, M. et al., “Antiviral drugs from the nucleoside analog family block volume-activated chloride channels,”Mol. Med.1(4):407-17 (1995).
Huminiecki, L. “Telomerase as a therapeutic target,”Acta Biochimica Polonica, 43(3):531-8 (1996).
Kondo, Y. et al., “Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis,”Oncogene16(17):2243-8 (1998).
Neidle, S. et al., “Commentary: Telomerase as an anti-cancer target: current status and future prospects,”Anti Cancer Drug Design, 14:341-347 (1999).
Rha, S. Y. et al., “Effect of telomere and telomerase interactive agents on human tumor and normal cell lines,”Clin. Cancer Res.6(3):987-93 (2000).
Viora, M. et al., “Interference with cell cycle progression and induction of apoptosis by dideoxynucleoside analogs,”Int. J. Immunopharmacol.19(6):311-21 (1997).
Au Jessie L.-S.
Wientjes M. Guillaume
Lewis Patrick
Mueller and Smith LPA
LandOfFree
Methods and compositions for modulating drug activity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for modulating drug activity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for modulating drug activity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3691628